Chronic Kidney Disease Market Growth Drivers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy MLYS?
Source: Newsfilter
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLYS
Wall Street analysts forecast MLYS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.320
Low
46.00
Averages
52.60
High
56.00
Current: 29.320
Low
46.00
Averages
52.60
High
56.00
About MLYS
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
MLYS Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: MLYS's 52-week low is $8.241 per share, while the high is $47.65, with the last trade at $28.26, indicating significant volatility in the stock price over the past year, reflecting varying market perceptions.
- Technical Indicator Focus: The current price of $28.26 is below the 200-day moving average, which may signal increased selling pressure in the short term, prompting investors to monitor subsequent market reactions to assess potential risks.
- Market Sentiment Assessment: Although the current price is significantly above the 52-week low, it remains below the high, suggesting a cautious market sentiment, necessitating investors to consider the overall market environment and the company's fundamentals in their decision-making.
- Investor Strategy Adjustment: Given the price fluctuations and changes in technical indicators, investors may need to reassess their holding strategies to manage potential market volatility and risk management needs.
See More
Mineralys Grants Stock Options to New Employees
- Stock Option Grants: On February 9, 2026, Mineralys Therapeutics awarded 33,504 stock options and 25,128 restricted stock units to two new non-executive employees, aimed at attracting talent and enhancing employee loyalty.
- Incentive Plan Details: The stock options will vest over four years, with 25% vesting in the first year and the remainder vesting at a rate of 1/48 each month, ensuring continued employee contributions during their tenure.
- Compliance Assurance: The grants comply with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to transparency and compliance in attracting new employees, which enhances investor confidence.
- Company Background: Mineralys focuses on developing medicines for hypertension and related comorbidities, with its lead candidate, lorundrostat, being an orally administered selective aldosterone synthase inhibitor, showcasing the company's innovative potential in the biopharmaceutical sector.
See More
Medical Properties Trust Options Volume Surges 120.3% Today
- Surge in Options Volume: Medical Properties Trust Inc (MPW) has seen an options volume of 76,796 contracts today, equating to approximately 7.7 million shares, which represents a significant 120.3% increase over its average daily trading volume, indicating heightened market interest in the stock.
- High-Frequency Trading Insight: Among these contracts, the $5.50 strike call option expiring on January 9, 2026, has been particularly active with 51,506 contracts traded, representing about 5.2 million underlying shares of MPW, suggesting a bullish sentiment among investors regarding future price movements.
- Market Dynamics: In comparison, Papa John's International, Inc. (PZZA) has recorded an options trading volume of 8,122 contracts today, representing approximately 812,200 shares, reflecting a 119.1% increase in trading volume and indicating active market engagement with the stock.
- Investor Sentiment: The $32.50 strike put option for PZZA expiring on February 20, 2026, has seen a trading volume of 6,108 contracts, representing about 610,800 shares, which suggests a cautious outlook among investors regarding the company's future performance.
See More
Mineralys Highlights Lorundrostat Clinical Progress, Anticipates 2026 Data Release
- Clinical Trial Progress: Mineralys Therapeutics completed enrollment for the Phase 2 Explore-OSA trial in Q3 2025, with topline results expected in Q1 2026, aimed at evaluating lorundrostat's efficacy in hypertensive patients with obstructive sleep apnea, potentially reinforcing its market position in hypertension treatment.
- New Drug Application Submission: The company submitted an NDA for lorundrostat to the FDA in late 2025, following three positive clinical trials demonstrating best-in-class safety and 24-hour blood pressure control across diverse patient populations, which is expected to enhance its recognition in the hypertension treatment market.
- Long-term Safety Study: The ongoing Transform-HTN open-label extension trial allows participants to continue receiving lorundrostat, aimed at gathering additional long-term safety and efficacy data to support future market launch efforts.
- Positive CKD Trial Results: The Explore-CKD Phase 2 trial showed that lorundrostat met its primary endpoint by significantly reducing systolic blood pressure and proteinuria in patients with hypertension, reduced kidney function, and albuminuria, further validating its potential in treating related diseases.
See More
Mineralys Therapeutics (MLYS) Shares Oversold with RSI at 29.3
- Oversold Signal: Mineralys Therapeutics (MLYS) shares have dropped to $35.48, with an RSI of 29.3, indicating that the recent heavy selling may be exhausting, prompting bullish investors to seek buying opportunities.
- Historical Performance Comparison: Over the past year, MLYS shares have seen a low of $8.241 and a high of $47.65, with the current trading price at $35.50, reflecting significant volatility that requires careful risk assessment by investors.
- Market Sentiment Analysis: Compared to the S&P 500 ETF (SPY) with an RSI of 55.2, MLYS's oversold condition may attract bullish investors' attention, potentially leading to a short-term rebound.
- Investment Opportunity Assessment: In an oversold scenario, investors should monitor MLYS's fundamentals and market dynamics to strategically invest at the right moment, capturing potential recovery opportunities.
See More
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
MLYS Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: MLYS's 52-week low is $8.241 per share, while the high is $47.65, with the last trade at $28.26, indicating significant volatility in the stock price over the past year, reflecting varying market perceptions.
- Technical Indicator Focus: The current price of $28.26 is below the 200-day moving average, which may signal increased selling pressure in the short term, prompting investors to monitor subsequent market reactions to assess potential risks.
- Market Sentiment Assessment: Although the current price is significantly above the 52-week low, it remains below the high, suggesting a cautious market sentiment, necessitating investors to consider the overall market environment and the company's fundamentals in their decision-making.
- Investor Strategy Adjustment: Given the price fluctuations and changes in technical indicators, investors may need to reassess their holding strategies to manage potential market volatility and risk management needs.
See More
Mineralys Grants Stock Options to New Employees
- Stock Option Grants: On February 9, 2026, Mineralys Therapeutics awarded 33,504 stock options and 25,128 restricted stock units to two new non-executive employees, aimed at attracting talent and enhancing employee loyalty.
- Incentive Plan Details: The stock options will vest over four years, with 25% vesting in the first year and the remainder vesting at a rate of 1/48 each month, ensuring continued employee contributions during their tenure.
- Compliance Assurance: The grants comply with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to transparency and compliance in attracting new employees, which enhances investor confidence.
- Company Background: Mineralys focuses on developing medicines for hypertension and related comorbidities, with its lead candidate, lorundrostat, being an orally administered selective aldosterone synthase inhibitor, showcasing the company's innovative potential in the biopharmaceutical sector.
See More
Medical Properties Trust Options Volume Surges 120.3% Today
- Surge in Options Volume: Medical Properties Trust Inc (MPW) has seen an options volume of 76,796 contracts today, equating to approximately 7.7 million shares, which represents a significant 120.3% increase over its average daily trading volume, indicating heightened market interest in the stock.
- High-Frequency Trading Insight: Among these contracts, the $5.50 strike call option expiring on January 9, 2026, has been particularly active with 51,506 contracts traded, representing about 5.2 million underlying shares of MPW, suggesting a bullish sentiment among investors regarding future price movements.
- Market Dynamics: In comparison, Papa John's International, Inc. (PZZA) has recorded an options trading volume of 8,122 contracts today, representing approximately 812,200 shares, reflecting a 119.1% increase in trading volume and indicating active market engagement with the stock.
- Investor Sentiment: The $32.50 strike put option for PZZA expiring on February 20, 2026, has seen a trading volume of 6,108 contracts, representing about 610,800 shares, which suggests a cautious outlook among investors regarding the company's future performance.
See More
Mineralys Highlights Lorundrostat Clinical Progress, Anticipates 2026 Data Release
- Clinical Trial Progress: Mineralys Therapeutics completed enrollment for the Phase 2 Explore-OSA trial in Q3 2025, with topline results expected in Q1 2026, aimed at evaluating lorundrostat's efficacy in hypertensive patients with obstructive sleep apnea, potentially reinforcing its market position in hypertension treatment.
- New Drug Application Submission: The company submitted an NDA for lorundrostat to the FDA in late 2025, following three positive clinical trials demonstrating best-in-class safety and 24-hour blood pressure control across diverse patient populations, which is expected to enhance its recognition in the hypertension treatment market.
- Long-term Safety Study: The ongoing Transform-HTN open-label extension trial allows participants to continue receiving lorundrostat, aimed at gathering additional long-term safety and efficacy data to support future market launch efforts.
- Positive CKD Trial Results: The Explore-CKD Phase 2 trial showed that lorundrostat met its primary endpoint by significantly reducing systolic blood pressure and proteinuria in patients with hypertension, reduced kidney function, and albuminuria, further validating its potential in treating related diseases.
See More
Mineralys Therapeutics (MLYS) Shares Oversold with RSI at 29.3
- Oversold Signal: Mineralys Therapeutics (MLYS) shares have dropped to $35.48, with an RSI of 29.3, indicating that the recent heavy selling may be exhausting, prompting bullish investors to seek buying opportunities.
- Historical Performance Comparison: Over the past year, MLYS shares have seen a low of $8.241 and a high of $47.65, with the current trading price at $35.50, reflecting significant volatility that requires careful risk assessment by investors.
- Market Sentiment Analysis: Compared to the S&P 500 ETF (SPY) with an RSI of 55.2, MLYS's oversold condition may attract bullish investors' attention, potentially leading to a short-term rebound.
- Investment Opportunity Assessment: In an oversold scenario, investors should monitor MLYS's fundamentals and market dynamics to strategically invest at the right moment, capturing potential recovery opportunities.
See More
